Clinical trials: Adult Acute Myeloid Leukemia
Leukemia, Nonlymphocytic, Acute
AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years
AML2003 is a prospective randomized trial, to investigate the value of early allogeneic stem cell transplantation in aplasia after induction therapy for high risk patients with acute myeloid leukemia.
- Trial name
- NCT00180102
- Testing
- Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone, early allogeneic PBSCT within induction therapy, autologous PBSCT
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Technische Universität Dresden
Acute Myeloid Leukemia
Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)
The study in patients with primary and secondary AML and high-risk MDS uses a risk-stratified, randomized design to evaluate the role of high-dose araC in induction, of G-CSF priming, and of autologous stem cell transplantation.
- Trial name
- NCT00266136
- Testing
- Cytarabine, Thioguanine, Daunorubicin
- Where
- Germany
- Volunteers
- 3,500 people
- Sponsor
- University Hospital Muenster
Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the MEK inhibitor MEK162 to see if it is safe in patients when combined with idarubicin and cytarabine.
- Conditions
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2)
- Trial name
- NCT02049801
- Testing
- MEK inhibitor MEK162, idarubicin, cytarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bruno C. Medeiros
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of miRisten in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous…
- Trial name
- NCT07025564
- Testing
- Biospecimen Collection, Echocardiography Test, miR-126 Inhibitor miRisten
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acute myeloid leukaemia.
- Trial name
- NCT04742101
- Testing
- S65487 and azacitidine
- Where
- 11 sites in France, Hungary and 4 more
- Volunteers
- 57 people
- Sponsor
- Institut de Recherches Internationales Servier
Hematologic Neoplasms
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
The primary objectives of Phase 1 Dose Escalation/Part 1 Expansion are: To assess the safety and tolerability of treatment with enasidenib administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle…
- Trial name
- NCT01915498
- Testing
- Enasidenib
- Where
- 24 sites in United States, France
- Volunteers
- 345 people
- Sponsor
- Celgene
Acute Myeloid Leukemia
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
This is a non-randomized, open-label, multicenter, dose escalation study designed to determine the maximum tolerated dose (MTD) of SL-401 in adult patients with acute myeloid leukemia, and to evaluate the safety profile of SL-401…
- Trial name
- NCT02270463
- Testing
- Tagraxofusp-erzs
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Stemline Therapeutics, Inc.
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
This phase II trial studies how well cyclophosphamide works in preventing chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01427881
- Testing
- cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia
Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission
The primary aim of this innovative immunotherapeutic study is to determine whether the antileukemic effects seen in our previous phase I/II study can be confirmed in a large cohort of patients and whether dendritic cell…
- Trial name
- WIDEA (NCT01686334)
- Testing
- DC vaccine
- Where
- 8 sites in Belgium
- Volunteers
- 130 people
- Sponsor
- Zwi Berneman
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, cytarabine, and idarubicin, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00093483
- Testing
- filgrastim, arsenic trioxide, cytarabine
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myeloid Leukemia
A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety, tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid leukemia (AML).
- Trial name
- NCT03760666
- Testing
- Brequinar/Brequinar + Ribavirin
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Clear Creek Bio, Inc.
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of vorinostat when given together with cytarabine and etoposide in treating patients with relapsed or refractory acute leukemia or myelodysplastic syndromes or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
- Trial name
- NCT00357305
- Testing
- vorinostat, cytarabine, etoposide
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Bone Marrow Suppression, Fever, Sweats, and Hot Flashes
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count.
- Conditions
- Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia
- Trial name
- NCT00003805
- Testing
- piperacillin sodium, piperacillin-tazobactam, tazobactam sodium
- Where
- 28 sites in United States, Belgium and 11 more
- Volunteers
- 859 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia (AML)
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
The purpose of this study is to learn more about the safety and efficacy of ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a gene mutation called IDH1 (isocitrate…
- Trial name
- NCT05907057
- Testing
- Ivosidenib 500mg Oral Tablet, Azacitidine
- Where
- 15 sites in Austria, France and 2 more
- Volunteers
- 245 people
- Sponsor
- Servier Affaires Médicales
Acute Myeloid Leukemia
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
The purpose of the phase 1b/2 study is to determine whether Onvansertib given orally daily for 5 consecutive days every 28 days is safe and tolerable in adult patients who have relapsed/refractory Acute Myeloid Leukemia (AML), or…
- Trial name
- NCT03303339
- Testing
- Onvansertib, Cytarabine, Decitabine
- Where
- 9 sites in United States
- Volunteers
- 72 people
- Sponsor
- Cardiff Oncology
Acute Myeloid Leukemia
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
This study will evaluate the efficacy, safety, and tolerability of entospletinib when administered as monotherapy or in combination with chemotherapy in adults with acute myeloid leukemia (AML).
- Trial name
- ENTO in AML (NCT02343939)
- Testing
- Entospletinib, Daunorubicin, Cytarabine
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 148 people
- Sponsor
- Gilead Sciences
Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations
This phase I trial studies the side effects and best dose of pacritinib when given together with chemotherapy in treating patients with acute myeloid leukemia that have an abnormal change (mutation) in the fms-related tyrosine…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Trial name
- NCT02323607
- Testing
- Pacritinib, Cytarabine, Daunorubicin Hydrochloride
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Bhavana Bhatnagar
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
This randomized phase II trial is studying the side effects and how well giving tipifarnib together with etoposide works in treating older patients with newly diagnosed, previously untreated acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00602771
- Testing
- tipifarnib, etoposide
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as cytarabine and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112554
- Testing
- cytarabine, laromustine
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 420 people
- Sponsor
- Vion Pharmaceuticals